Sterling Technology | Virtual Data Rooms’ Post

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our new podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. In this third episode, we consider the challenges associated with defining and valuing digital assets. Aligning the target’s and acquiror’s views on valuation is obviously key to getting a deal done. Digital assets present some unique challenges for pharmaceutical companies more used to valuing molecules in traditional licensing or acquisition transactions. What techniques do they need to deploy to overcome this hurdle? To listen and download the report accompanying the series, please follow the link at the bottom. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #corporatefinance #venturecapital #privateequity https://lnkd.in/earYDgs5

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks and avoid failure. In previous episodes, we’ve covered key areas of difference between traditional life science transactions and the new world of digital dealmaking including corporate culture, information governance, defining and valuing the asset, and due diligence. In this fifth and final conversation, we pull these strands together and discuss how they influence transaction structure and terms – which both parties must agree on to bring any deal to a successful conclusion. To listen, follow the link at the bottom. You can also download the report accompanying the series. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #privateequity #venturecapital #corporatefinance https://lnkd.in/eFJsDmw8

🎙 Dive into Sterling Technology | Virtual Data Rooms new podcast series with industry veteran John Easton. Discover how digital assets are transforming transactions in Life Science. Gain key insights on deal success and risk mitigation. Don't miss out! 🎙

Are you ready for a digital-first future in #lifesciences dealmaking? Transactions involving digital assets are an increasing focus for #pharmaceuticals, #medicaldevice and #medtech companies. In our new podcast series, life sciences industry M&A veteran John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure. Culture clash? In this first episode we consider cultural differences between life science and technology companies and the implications those differences have for digital dealmaking. To listen and download the report accompanying the series, please follow the link at the bottom. Essential information for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving #artificialintelligence, #machinelearning and #bigdata, our five-part series and accompanying report provide insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. #mergersacquisitionsdivestitures #corporatefinance #venturecapital #privateequity https://lnkd.in/e7qNw34E

What a year for Seuss+! As we wrap up 2023, we are proud to reflect on our journey marked by collaboration and knowledge-sharing. From launching the inspiring 'Cut the Chat' podcast, offering free four-day email courses, to hosting impactful webinars on navigating the evolving landscape of clinical research, it's been a year of enriching dialogues and insights. We are excited about the strides we have made with our biotech, pharma, specialty supplier, and CRO clients. But most of all, we are proud of the progress we've made together in this ever-evolving industry. As we head towards another year, our commitment remains strong - insightful conversations, problem-solving, and continued knowledge sharing. Get to know our leadership team and more in our end-of-year wrap-up article on our website. Let's continue to learn, grow, and create positive impact in life sciences together. [Read the article👈] https://hubs.ly/Q02dsX030 #SeussPlus #YearInReview #KnowledgeSharing #ClinicalResearch #Biotech #Pharma #CRO

The #biotech industry is going through its worst period in decades, as can be seen in distorted stock market valuations. Many high-quality listed biotech companies are imho seriously undervalued, some trading near or below cash. This presents a tremendous opportunity, and I believe that biotech will emerge as one of the top-performing asset classes over the next two years.   One massive structural shift I’m seeing is the resounding success of Ozempic and other GLP-1 agonists, combined with shifting societal norms, which is poised to revolutionize our perspective on scientific potential and the utilization of medications. I believe this will redefine the very essence of the pharmaceutical industry. We’re entering a new era in which medicine will not only treat "illnesses" but also empower individuals to modify, reshape, and enhance themselves according to their wants, needs and desires, in consultation with their respective medical practitioners.   I discuss this and other structural changes and opportunities in the Biotech2050 podcast with Alok Tayi, PhD. Check it out:   #investing #future https://lnkd.in/eWuWQdUM  

🧬 Bridging the gap between R&D and process development will help accelerate product development In our latest Ori Spotlight podcast episode, Jason C. Foster welcomed Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss how equipping researchers with advanced manufacturing technology early on in the development process will accelerate the journey to GMP. Implementing continual methodologies and equipment from research through GMP production can significantly streamline workflows, enhance efficiency, and speed up the journey from lab to patient. To overcome manufacturing hurdles and maximize the reach of advanced therapies, biopharma should be thinking early on about integrated approaches that span the entire development pipeline. This comprehensive strategy is essential for scaling impact, making these life-changing treatments more accessible and affordable for patients globally. 🎧 Listen on Spotify: https://lnkd.in/dmSEXjPp 📺 Watch on Youtube: https://lnkd.in/dcsYjjCZ #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

A few weeks ago CEO/Founder Darwin Shurig hosted a webinar featuring some top leaders in the MedTech space, Tanima Ghosh, Justin Bushko, and Michel E. Moravia, MSE, MBA. This webinar was on "Design Verification From Initiation to Commercial Launch". In this short clip, Tanima begins talking about feasibility and some of the key elements when taking a product through the feasibility phase. Click here to view the full webinar, and subscribe to the SSI YouTube channel for more webinar and podcast content! https://lnkd.in/eJj46seK #MedTech #MedicalDevice #Pharma #IndustryInsights #DesignControls #ProductLaunch #ClinicalTrials #DesignVerification #Validation #DesignQuality #TalentManagement #Quality #Regulatory #Manufacturing

Don’t miss the Quality Means Business Founder/CEO Michel E. Moravia, MSE, MBA as he shares his insights on “Design Verification from Initiation to Commercial Launch” alongside top leaders in the MedTech space! A huge thank you to Shurig Solutions, Inc. for hosting this insightful webinar! #QualityMeansBusiness #quality #designverification #regulatory #manufacturing #medicaldevices #validation #combinationproducts

Greed kills the mission. Steve Gorlin (who does not appear to have an active LinkedIn profile; imagine that!) slips in a "don't be greedy" in the middle of a steady stream of stories from a long career in biotech on today's #BusinessOfBiotech. It stuck with me all day. Here's a guy, serially successful who's boasting about making his first million, advising me to not be greedy. Eventually, it settled in. Gorlin's not warning against the pursuit of success. It's just gotta be for the right reasons, and getting rich is a dead end. Create a valuable product that people need, build a system around it that can support it through high points and low ones, put the right people in the right places, and the success comes in all different ways, including cash. Check out today's podcast. It's a good listen.